Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 6Head & Neck 3Lymphoid 2Gynecologic 2Gastrointestinal 2Dermatologic 2Genitourinary 1CNS 1Breast 1

Conditions

Glioblastoma 3Ovarian Neoplasms 1Melanoma 1Lymphoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Glioma 1Colorectal Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 19Radiosurgery 16Radiotherapy 14Specimen Handling 11Pemetrexed 8Paclitaxel 6Erlotinib Hydrochloride 6Docetaxel 6Carboplatin 6Bevacizumab 5pembrolizumab 4Temozolomide 4Spinal Puncture 4Cisplatin 4osimertinib 3Taxes 3Nivolumab 3Gemcitabine 3Gefitinib 3Filgrastim 3Drug Therapy 3trametinib 2selpercatinib 2sapanisertib 2motexafin gadolinium 2epothilone B 2dabrafenib 2X-Rays 2Vorinostat 2Trastuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × epacadostat × CNS × Clear all
NCT02327078 2025-08-14

A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)

Incyte Corporation

Phase 1/2 Completed
307 enrolled 27 charts
CNSDermatologicGastrointestinalGynecologicHead & NeckLymphoidThoracic

Glioblastoma, Head and Neck Neoplasms, Lung Neoplasms, Lymphoma, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡